Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 641-650

  Shu, Guo Shun ^a   Lv, Fang ^a   Yang, Zhu Lin ^a   Miao, Xiong Ying ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

c Myb; Chronic cholecystitis; Gallbladder cancer; Gallbladder polyp; Immunohistochemistry; p53; p53 up regulated modulator of apoptosis

Indexed keywords

PROTEIN C MYB; PROTEIN P53; PUMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CHRONIC CHOLECYSTITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GALLBLADDER ADENOCARCINOMA; GALLBLADDER CANCER; GALLBLADDER EPITHELIUM; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYP; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADICAL RESECTION; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CHOLECYSTITIS; FEMALE; GALLBLADDER; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYB; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84882618695     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0431-7     Document Type: Article

References (54)

1. Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591-1602
2. Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin North Am 39:331-342
3. Srivastava K, Srivastava A, Sharma KL et al (2011) Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat Res 728:67-79
4. Gatto M, Bragazzi MC, Semeraro R et al (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42:253-260
5. Zhu AX, Hezel AF (2011) Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 53:695-704
6. Tucek S, Tomasek J, Halámkova J (2010) Bile duct malignancies. Klin Onkol 23:231-241
7. Legan M, Luzar B, Marolt VF et al (2006) Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 12:3425-3429
8. Chuang SC, Lee KT, Tsai KB et al (2004) Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 28:995-1000
9. Puhalla H, Kandioler D, Ludwig C et al (2004) p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res 24:1201-1206
10. Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP 53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50-56
11. Kandioler-Eckersberger D, Kappel S, Mittelbock M et al (1999) The TP 53 genotype but not the immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III nonsmall cell lung cancer. J Thorac Cardiovasc Surg 117:744-750
12. Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F et al (2002) TP 53 genotype but not p53 immunohistochemical result predicts response to preoperative short term radiotherapy in rectal cancer. Ann Surg 235:493-498
13. Gannon JV, Greaves R, Iggo R et al (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595-1602
14. Morton JP, Timpson P, Karim SA et al (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107:246-251
15. Middelburg R, de Haas RR, Dekker H et al (2005) Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 11:1863-9186
16. Villunger A, Michalak EM, Coultas L et al (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302:1036-1038
17. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673-682
18. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683-694
19. Liu Z, Lu H, Shi H et al (2005) PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res 65:1647-5164
20. Li J, Lee B, Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 281:7260-7270
21. Cheng EH, Wei MC, Weiler S et al (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8:705-711
22. Hacki J, Egger L, Monney L et al (2000) Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 19:2286-2295
23. Yu J, Yue W, Wu B et al (2006) PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12:2928-2936
24. Yu F, Watts RN, Zhang XD et al (2006) Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs 17:1151-1161
25. Liu HF, Hsiao PW, Chao JI (2008) Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chem Biol Interact 176:48-57
26. Tanikawa J, Nomura T, Macmillan EM et al (2004) p53 suppresses c-Myb-induced trans-activation and transformation by recruiting the corepressor mSin3A. J Biol Chem 279:55393-55400
27. Schmidt M, Nazarov V, Stevens L et al (2000) Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis. Mol Cell Biol 20:1970-1981
28. Kowenz-Leutz E, Herr P, Niss K et al (1997) The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation. Cell 91:185-195
29. Kanei-Ishii C, Tanikawa J, Nakai A et al (1997) Activation of heat shock transcription factor 3 by c-Myb in the absence of cellular stress. Science 277:246-248
30. Weston K (1999) Reassessing the role of C-MYB in tumorigenesis. Oncogene 18:3034-3038
31. Ramsay RG, Gonda TJ (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8:523-534
32. Sala A, Casella I, Grasso L et al (1996) Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53. Cancer Res 56:1991-1996
33. Tanikawa J, Ichikawa-Iwata E, Kanei-Ishii C et al (2000) p53 suppresses the c-Myb-induced activation of heat shock transcription factor 3. J Biol Chem 275:15578-15585
34. Yamagiwa H, Tomiyama H, Yoshimura H (1986) Histogenesis of carcinoma of gallbladder. Histolohical study of serial sections of 1000 cases of resected gallbladder. Rinsho Byori 34:475-480
35. Dowling GP, Kelly JK (1986) The histogenesis of adenocarcinoma of the gallbladder. Cancer 58:1702-1708
36. Sanada Y, Yoshida K, Ohara M et al (2007) Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 13:105-113
37. Chang HJ, Yoo BC, Kim SW et al (2007) Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13:326-335
38. Augenlicht LH (2001) Clinical response to fluorouracil and p53. N Engl J Med 345:1065
39. Watanabe T, Wu TT, Catalano PJ et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206
40. Puhalla H, Wild T, Filipits M et al (2001) Der prognostische Wert der p53 Immunhistochemie beim Gallenblasenkarzinom. Acta Chir Austr 33:85-88
41. Quan ZW, Wu K, Wang J et al (2001) Association of p53, p16 and vascular endothelial growth factor expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 193:380-383
42. Diamantis I, Karamitopoulou E, Perentes E et al (1995) p53 protein immunoreactiviy in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Histopathology 22:774-779
43. Kandioler-Eckersberger D, Kappel S, Mittelbock M et al (1999) The TP 53 genotype but not the immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III nonsmall cell lung cancer. J Thorac Cardov Sur 117:744-750
44. Ray RM, Bhattacharya S, Johnson LR (2011) Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 16:35-44
45. Sinicrope FA, Rego RL, Okumura K et al (2008) Prognostic impact of bin, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 14:5810-5818
46. Karst AM, Dai DL, Martinka M et al (2005) PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 24:1111-1116
47. Diallo JS, Aldejmah A, Mouhim AF et al (2007) NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 13:7044-7052
48. Jansson A, Arbman G, Sun XF (2004) mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol Rep 12:1245-1249
49. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN et al (2010) Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 57:304-316
50. Brabender J, Lord RV, Danenberg KD et al (2001) Increased C-myb mRNA expression in Barretts esophagus and Barretts-associated adenocarcinoma. J Surg Res 99:301-306
51. Gonda TJ, Leo P, Ramsay RG (2008) Estrogen and MYB in breast cancer: potential for new therapies. Expert Opin Biol Ther 8:713-717
52. Wilkins HR, Doucet K, Duke V et al (2010) Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing C-myb protein, and decreasing transcription of the anti-apoptosis protein bcl-2. Tumor Biol 31:16-22
53. Yang H, Huang ZZ, Wang J et al (2001) The role of C-myb and SP1 in the up-regulation of methionine adenosyl transferase 2A gene expression in human hepatocellular carcinoma. FASEB J 15:1507-1516
54. Narnberg W, Artue M, Nawrath M et al (1995) Human C-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. Cancer Res 55:4432-4437